Medplus Health Services

Brokerage firm Nomura noted that weak quarterly results were led by private label slowdowns and rising overhead expenses.

In the March quarter (Q4FY26), Medplus Health reported a net profit of ₹63.97 crore, as compared to ₹51.32 crore a year ago, up 24.6 per cent

The selling pressure on the counter came after the company's subsidiary, Optival Health Solutions, received a suspension order for a drug license of a store situated in Karnataka

Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.

Technical charts suggest that microcap stocks such as Cyient DLM, Sansera Engineering, AMI Organics, Aarti Pharmalabs and Medplus Health Services can potentially rally up to 23% from present levels.

MedPlus continued to benefit from strong sales of products under its private label brands in both the pharmaceuticals and consumer wellness categories

Drugmakers Mankind Pharma's and Cipla's domestic revenues were boosted by strong demand for OTC medications, the companies said in their second-quarter earnings statements

The company reported consolidated net profit of Rs 38.74 crore ($4.6 million) for the quarter ended Sept. 30, compared to Rs 14.56 crore a year ago

The surge in Medplus Health shares came after the company announced that it has received a stay order against the suspension order of a store in Vikhroli, Maharashtra.

The public promoter of Medplus Health Services sold its entire stake worth Rs 836 crore through open market transactions on Monday

Growth in the retail pharmaceutical sector has improved and is expected to sustain, according to analysts, as an improvement in medical infrastructure has resulted in better access to these platforms

In Europe, markets closed higher in the previous session after the Bank of England maintained its interest rates at a 16-year high of 5.25 per cent, as widely anticipated

Stocks to watch on May 29: Wockhardt reported its Q4 earnings, disclosing a net loss of Rs 177 crore compared to a loss of Rs 237 crore YoY

MedPlus competes with Reliance-owned Netmeds and Apollo Pharmacies among other retail pharmacies in the Indian OTC drugs market

The company's board on Wednesday decided to defer the expansion plans for Diagnostics Division beyond Hyderabad, until the profitability of the pilot project was established.

MedPlus Health Services, a retail pharmacy and diagnostics chain in India, is set to elevate its "store generics" (in-house brand) to 50-60 per cent contribution to the firm's revenues in the next two to three years, drawing inspiration from the successful practices of US pharma retail giants like Walgreens and CVS. The concept of "store generics" involves a retail chain exclusively selling its own branded medications alongside innovator drugs. MedPlus currently witnesses around 12 per cent of its revenues from store generics. This strategic move follows the triumphant adoption of the "store generics" model in Telangana and subsequent expansions into Andhra Pradesh, Tamil Nadu, Karnataka, Maharashtra, West Bengal, and Odisha, Gangadi Madhukar Reddy, MD CEO of MedPlus said. Over the past six months, MedPlus has witnessed over 26.2 lakh customers saving a substantial Rs. 139.7 crores by opting for MedPlus brands, he said. To ensure the quality and efficacy of their medications, MedPl

As per reports, PI Opportunities Fund and Lavender Rose Investment Ltd were, together, looking to pare their up to 8 per cent stake in the company

India's MedPlus Health Services reported a 18.3% rise in first-quarter profit on Monday as increased presence of the pharmacy helped drive its retail sales

With the recent decline in the stock price of the company, MHSL is trading 7 per cent lower from its issue price of Rs 796 per share